21
ALL1
Aequus Pharmaceuticals1
Biocon1
BNS Ophthalmics1
Cook MyoSite1
Glenmark Pharmaceuticals2
Lipella Pharmaceuticals1
Mankind Pharma2
Marinomed Biotech1
Nexus Pharmaceuticals1
Orca Bio9
TFF PharmaceuticalsYear
21
ALL2
20255
20244
20231
20222
20217
2020DEALS // DEV.
21
ALL5
Deals16
DevelopmentsCountry
21
ALL2
AUSTRIA1
CANADA3
INDIA1
ISRAEL14
U.S.A21
ALL1
BioNanoSim16
Inapplicable1
Jefferies1
Lipella Pharmaceuticals1
Panacea Biotec Limited1
Sandoz B2BTherapeutic Area
21
ALL1
Dermatology15
Immunology1
Obstetrics/Gynecology (Women’s Health)1
Oncology1
Ophthalmology2
UrologyStudy Phase
21
ALL5
Approved FDF1
Phase III13
Phase II1
Phase I1
PreclinicalDeal Type
21
ALL3
Agreement1
Collaboration1
Financing16
InapplicableProduct Type
21
ALL20
Antibiotic1
Cell and Gene therapyDosage Form
21
ALL2
Injection1
Intravenous Infusion2
Intravesical Injection1
Intravitreal Injection2
Nasal Powder for Inhalation2
Ophthalmic Solution3
Oral Capsule6
Oral Powder for Inhalation1
Oral Tablet, Immediate Release1
Powder for InhalationLead Product
21
ALL1
Orca-T20
TacrolimusTarget
21
ALL15
Calcineurin phosphatase5
FK506 binding protein 1A1
UndisclosedLead Product(s) : Tacrolimus
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Panacea Biotec Limited
Deal Size : $251.1 million
Deal Type : Agreement
Panacea Biotec Sells Domestic Formulation Assets To Mankind Pharma for Rs 1,908 Crore
Details : The top selling brands are Pangraf (tacrolimus), Alphadol (alfacalcidol), Cilamin (penicillamine) & Livoluk Fibre (lactulose in combination with ispaghula) were ranked number 1, whereas Glizid (Gliclazide + Metformin), Mycept (Mycophenolate Mofetil) were...
Product Name : Pangraf
Product Type : Antibiotic
Upfront Cash : Undisclosed
January 02, 2022
Lead Product(s) : Tacrolimus
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Panacea Biotec Limited
Deal Size : $251.1 million
Deal Type : Agreement
Lead Product(s) : Orca-T,Tacrolimus
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Orca Bio’s Orca-T Shows Positive Phase 3 Data in Hematologic Malignancies
Details : Orca-T is an investigational allogeneic T-cell immunotherapy being evaluated in clinical trials for the treatment of acute myeloid leukemia.
Product Name : Orca-T
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Orca-T,Tacrolimus
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Receives FDA Approval for Tacrolimus Injection
Details : Tacrolimus is a macrolide antibiotic with immunosuppressive properties, binds to FK506 binding protein inhibiting calcineurin phosphatase, received approval for organ rejection.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 13, 2025
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder for Lung Transplant
Details : The company’s lead product candidate TFF TAC (tacrolimus) inhalation powder, is undergoing Phase 2 trial studies for the prevention of lung transplant rejection.
Product Name : TFF TAC
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 24, 2024
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TFF Reports Positive Phase 2 Data for Tacrolimus Powder in Lung Transplant Rejection
Details : The company’s lead product candidate TFF TAC (tacrolimus) inhalation powder, is undergoing Phase 2 trial studies for the prevention of lung transplant rejection.
Product Name : TFF TAC
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 08, 2024
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TFF Pharmaceuticals Updates on Tacrolimus Inhalation Powder Phase 2 Trial
Details : The company’s lead product candidate TFF TAC (tacrolimus) inhalation powder, is undergoing Phase 2 trial studies for the prevention of lung transplant rejection.
Product Name : TFF TAC
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 15, 2024
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biocon Receives Approval for Tacrolimus Capsules from SAHPRA
Details : Tacrograf (tacrolimus) is a next-generation, capsule formulation immunosuppressent for the treatment and prevention of prophylaxis of organ rejection after transplant.
Product Name : Tacrograf
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 20, 2024
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TFF Pharmaceuticals Presents Interim Data from Phase 2 Study of Tacrolimu
Details : TFF TAC (tacrolimus) is a next-generation, direct-to-lung, inhaled dry powder formulation of tacrolimus for the treatment and prevention of prophylaxis of organ rejection in lung transplant.
Product Name : TFF TAC
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 25, 2024
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TFF TAC (tacrolimus) is a next-generation, direct-to-lung, inhaled dry powder formulation of tacrolimus for the treatment and prevention of prophylaxis of organ rejection in lung transplant.
Product Name : TFF TAC
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 19, 2023
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tacrolimus
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10
Details : LP-10 is a proprietary liposomal formulation of tacrolimus that is currently being evaluated as a treatment for moderate to severe hemorrhagic cystitis. The product candidate is currently in Phase 2a clinical trial.
Product Name : LP-10
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : Tacrolimus
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable